Hayat Sawsan Johar, Uppal Sukhbir Singh
Department of Medicine, Mubarak Al-Kabeer Hospital, Ministry of Health, Jabriya, Kuwait.
Mod Rheumatol. 2007;17(2):174-7. doi: 10.1007/s10165-006-0561-8. Epub 2007 Apr 20.
Since levels of the proinflammatory cytokine tumor necrosis factor alpha (TNFalpha) are significantly increased in systemic lupus erythematosus (SLE) and may be involved in the disease pathogenesis, we report on the safety and efficacy of infliximab, a chimeric monoclonal antibody directed against TNFalpha, given to a patient with difficult-to-treat active nonrenal SLE. This patient, who failed to remit with full doses of glucocorticoids, hydroxychloroquine, methotrexate, and azathioprine, went into sustained remission with the addition of infliximab infusions. Glucocorticoids could be tapered off completely.
由于促炎细胞因子肿瘤坏死因子α（TNFα）的水平在系统性红斑狼疮（SLE）中显著升高，且可能参与疾病发病机制，我们报告了英夫利昔单抗（一种针对TNFα的嵌合单克隆抗体）用于治疗难治性活动性非肾脏SLE患者的安全性和有效性。该患者在使用全剂量糖皮质激素、羟氯喹、甲氨蝶呤和硫唑嘌呤治疗后未能缓解，在加用英夫利昔单抗输注后进入持续缓解状态。糖皮质激素可完全减量。
